Enzalutamide and Apalutamide: In Vitro Chemical Reactivity Studies and Activity in a Mouse Drug Allergy Model-Reference-Cited by-同舟云学术

Enzalutamide and Apalutamide: In Vitro Chemical Reactivity Studies and Activity in a Mouse Drug Allergy Model

Published:2019-09-20 Issue:1 Volume:33 Page:211-222
ISSN:0893-228X
Container-title:Chemical Research in Toxicology
language:en
Short-container-title:Chem. Res. Toxicol.

Author:

Ji Changhua¹^ORCID,Guha Mausumee¹^ORCID,Zhu Xu²^ORCID,Whritenour Jessica²^ORCID,Hemkens Michelle¹,Tse Susanna³^ORCID,Walker Gregory S.³^ORCID,Evans Ellen²^ORCID,Khan Nasir K.⁴^ORCID,Finkelstein Martin B.⁴^ORCID,Callegari Ernesto³^ORCID,Obach R. Scott³^ORCID

Affiliation:

1. Drug Safety Research and Development, Pfizer Inc., La Jolla, California 92037, United States

2. Drug Safety Research and Development, Pfizer Inc., Groton, Connecticut 06340, United States

3. Pharmacokinetics, Dynamics, and Drug Metabolism, Pfizer Inc., Groton, Connecticut 06340, United States

4. Drug Safety Research and Development, Pfizer Inc., Pearl River, New York 10965, United States

Funder

Pfizer

Publisher

American Chemical Society (ACS)

Subject

Toxicology,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.chemrestox.9b00247

Reference26 articles.

1. ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment

2. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

3. XTANDI (enzalutamide) [prescribing information]. Astellas Pharma U.S., Inc., Northbrook, IL 2018. Revised: July 2018. Available at https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf. Accessed May 18, 2019.

4. ERLEADA (apalutamide) [prescribing information]. Janssen Pharmaceutical Companies, Horsham, PA. Issued: February 2018. Available at http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/ERLEADA-pi.pdf. Accessed May 11, 2019.

5. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cutaneous Adverse Reactions to Apalutamide: Case Series with Clinical and Pathological Correlations;Acta Dermato-Venereologica;2024-09-04

2. Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study;International Journal of Clinical Oncology;2024-05-20

3. Real-world analysis of apalutamide-associated skin rash in Chinese patients with prostate cancer;World Journal of Urology;2024-03-20

4. Case report: Apalutamide-induced severe lethal cutaneous adverse effects in China;Frontiers in Immunology;2024-01-11

5. 2-cyanopyridine derivatives enable N-terminal cysteine bioconjugation and peptide bond cleavage of glutathione under aqueous and mild conditions;RSC Advances;2024